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http://dx.doi.org/10.1016/j.kjms.201Abstract Cisplatin-induced acute kidney injury (AKI) is a major concern among clinicians in
prescribing cisplatin-based chemotherapy. This study evaluated and compared the ability of
urinary biomarkers, including urinary neutrophil gelatinase-associated lipocalin (NGAL), cysta-
tin C, and the urinary albumin to creatinine ratio (ACR) to predict cisplatin-induced AKI.
Thirty-three cancer patients receiving cisplatin-based chemotherapy were prospectively
studied, including 10 (30%) who developed AKI (the study group). Changes of urinary
biomarkers were compared at 4 hours, 8 hours, and 12 hours, and 1 day, 2 days, 3 days, and
4 days after cisplatin intravenous infusions (75 mg/m2) versus the baseline. There was a signif-
icant increase in urinary NGAL levels from 12 hours to 4 days (p< 0.05) compared to baseline
after cisplatin infusion in the AKI group. The magnitude of these changes over time differed
significantly by group (p< 0.001). The area under the receiver operating curve describing
the relationship between urinary NGAL levels and AKI within 12 hours was 0.865 (95%Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung
ad, Kaohsiung 807, Taiwan.
(J.-Y. Guh).
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2.10.004
Urinary NGAL and cisplatin-induced AKI 305confidence intervalZ 0.691e1.000). Urinary NGAL levels independently predicted AKI 12 hours
after cisplatin (pZ 0.045) after adjustments for age, gender, body mass index, baseline serum
creatinine, and urinary total protein. Urinary NGAL levels may be an early biomarker of AKI in
patients receiving cisplatin-based treatment.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Cisplatin, found in the 1960s to inhibit cell division, is
currently one of the most widely used anticancer chemo-
therapy drugs [1,2]. Among the current chemotherapy
medications, cisplatin and platinum-related medications
are mainly used for head and neck cancer, esophageal
cancer, genital cancer (i.e., testicular and ovarian cancer),
cervical cancer, and non-small-cell lung cancer [3,4].
Current studies show that the mechanisms for tumor
suppression of cisplatin are to crosslink DNA and interfere
with its replication and synthesis [5,6].
Although cisplatin is used widely, its adverse clinical
effects, including neurotoxicity, ototoxicity, nephrotoxi-
city, nausea, and vomiting, remain challenging for clini-
cians [7]. Researchers and clinicians have exerted efforts to
remove or circumvent these side effects, such as devel-
oping new platinum analogs with less toxicity. The most
well known is carboplatin, which has less nephrotoxicity
[8]. Other ways of preventing cisplatin-induced kidney
injury include giving large amounts of intravenous fluids
and mannitol [9,10]. However, increasing numbers of
studies are revealing that, even with these management
methods, around one-third of the patients receiving
cisplatin-based chemotherapy suffer acute kidney injury
(AKI) [2,11]. Clinically, cisplatin-induced AKI occurs about
10 days after cisplatin treatment, and it is marked by
a decline in glomerular filtration rates, increased serum
creatinine levels, hypomagnesemia, and hypokalemia [2,7].
The pathologic changes in cisplatin-induced AKI involve
renal tubular cell damage [7], and the mechanisms of
cisplatin-induced renal tubular cell damage include
apoptosis, which is induced by activated caspase-8 and
which causes cellular stress and the release of apoptogenic
factors [12], endoplasmic reticulum stress [13], p53 acti-
vation [7], mitogen-activated protein kinase activation
[14], oxidative stress [15], and inflammation by induced
tumor necrosis factor-a [16].
From the risk, injury, and failure; and loss; and end-
stage kidney disease (RIFLE) criteria [17] and the AKI
Network criteria [18], the Acute Dialysis Quality Initiative
Group has tried to redefine and prevent AKI. These criteria
are based on serum creatinine levels and calculations of
the estimated glomerular filtration rate (eGFR), but many
studies have revealed that serum creatinine levels do not
parallel acute kidney damage and using these as criteria
may delay clinical diagnosis [19,20]. New AKI biomarkers
use therefore necessary. Recent studies have investigated
some biomarkers for AKI [21], including neutrophil
gelatinase-associated lipocalin (NGAL), which is a 25-kDa
protein. NGAL has a very low concentration in most
human tissues but spikes when kidney, liver, colon, andlung epithelial cells are damaged [22]. In animal models,
NGAL levels increase after ischemic kidney injury or
exposure to nephrotoxic drugs [23]. From the results of
several human prospective studies, NGAL may be a more
sensitive biomarker than creatinine in predicting AKI
[24,25].
Cystatin C (Cys C), which is a 13-kD cysteine proteinase
inhibitor protein, filters through the glomerulus and is
reabsorbed by proximal tubule cells without secretion
[26]. In animal studies, urinary Cys C predicts AKI earlier
than other biomarkers [27]. In a prospective study of 123
adults who underwent cardiac surgery and who suffered
AKI according to the AKI Network criteria, urinary Cys C
levels predicted AKI best when patients were admitted to
the intensive care unit [area under the curve (AUC)Z
0.70, p< 0.001]. Urinary NGAL levels best predicted AKI
6 hours after intensive care unit admission (AUCZ 0.88;
p< 0.001) [28].
Proteinuria is a marker of chronic kidney disease. A
cohort study observed that, in patients who had coronary
artery bypass graft surgeries, the severity of preoperative
proteinuria reflected the stage of acute ischemic kidney
injury after the operation [29]. The Atherosclerosis Risk in
Communities study enrolled 11,200 patients in order to
evaluate the relationship between proteinuria and AKI. The
results showed that the risk of AKI increased with the
severity of albuminuria [30].
Although clinicians have exerted efforts to prevent
cisplatin-induced AKI, the results are not satisfactory [7]. A
biomarker that predicts AKI earlier than serum creatinine
levels may provide clinicians with more time to apply the
appropriate intervention. In an animal study, urinary NGAL
levels that were measured by western blots were increased
within 3 hours after cisplatin treatment in an AKI study
group [31]. In a human prospective study, 12 patients (26%)
had serum creatinine levels that were increased by over
25% 5.8 2.3 days after cisplatin as compared to baseline.
Urinary NGAL levels increased significantly more in cases
than in controls on Days 1, 2, 3, and 15, whereas serum
creatinine levels were increased significantly on Days 3, 7,
and 15 [32]. Serum Cys C levels have also been shown to be
a more sensitive marker than creatinine levels in cisplatin
chemotherapy, with a 21% increase without a significant
creatinine change [33]. However, no studies have so far
evaluated the role of urinary Cys C levels in cisplatin-
induced AKI.
This study measured and compared urinary biomarkers
in order to determine which can predict cisplatin-induced
AKI earlier. This prospective cohort study compared NGAL
levels, Cys C levels, and the urinary albumin to creatinine
ratio (ACR) at several time points in cancer patients who
suffered from cisplatin-induced AKI.
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Patients
This study enrolled cancer patients older than 18 years with
pathologically diagnosed head and neck cancer, esophageal
cancer, or thymic cancer who were indicated for cisplatin-
based chemotherapy and admitted to the Kaohsiung
Medical University Hospital Hematology and Oncology ward
from August 2009 to August 2010. Eastern Cooperative
Oncology Group Performance Statuses of 0e1 were another
inclusion criterion. The exclusion criteria consisted of the
use of any nephrotoxic drugs before chemotherapy,
eGFR< 60 mL/min/1.73 m2, and confounding factors that
could interfere with renal function, including sepsis and the
use of contrast medium examination. The hospital’s Insti-
tutional Review Board (KMUH-IRB-980216) approved this
study.
Study design
Baseline serum and urinary biochemistry examinations
were performed on all patients before cisplatin-based
chemotherapy. After baseline evaluation of renal function
and urinary profile, 500 mL of 0.9% isotonic saline con-
taining 1 g of magnesium sulfate and 75 mg/m2 of cisplatin
in 750 mL of 0.9% normal saline with 250 mL mannitol for 4
hours were infused. From the start to the end of cisplatin
infusion, 500 mL of 0.9% isotonic saline and 1 L 10%
dextrose solution were infused from another venous line.
Large amounts of hydration, including 1 L of 0.9% isotonic
saline and 1 L 10% dextrose solution/day, were given to
patients from Day 1 to Day 6 in order to prevent cisplatin-
induced AKI. Betamethasone (4 mg) was administered
every 6 hours from Day 1 to Day 5, and tropisetron hydro-
chloride (5 mg) was prescribed before chemotherapy as an
antiemetic.
Urinary samples were collected for biochemical studies
at 4 hours, 8 hours, and 12 hours and 1 day, 2 days, 3 days,
and 4 days after cisplatin infusion. The urinary samples
were separated in order to measure creatinine and albumin
immediately and then stored at 80 C until the NGAL and
Cys C analysis. In order to evaluate if patients had AKI,
serum creatinine levels on Days 4 and 10 after cisplatin
infusion were collected and measured. All serum
biochemical parameters were measured on Day 10 after
cisplatin infusion in order to evaluate body changes.
Assay
Urinary NGAL concentrations were measured by a NGAL
enzyme-linked immunosorbent assay kit (BioPorto, Gen-
tofte, Denmark). The inter- and intra-assay coefficients of
variance for NGAL were 3.4% and 4.7%, respectively.
Urinary Cys C levels were measured by particle-enhanced
immunonephelometry assay with an automatic device (N
Latex Cystatin C, BN ProSpec; Siemens Healthcare Diag-
nostics Inc., Tarrytown, NY, USA). The inter- and intra-assay
coefficients of variance were 1.7% and 2.9%, respectively.
Serum and urinary creatinine levels were measured by the
enzyme method, while urinary albumin levels weremeasured by an immunoturbidimetric assay. These
biochemical concentrations were all measured by an
automatic device (Cobas Integra 400; Roche Diagnostics,
Basel, Switzerland).
The eGFRs were estimated by the following isotope dilu-
tion mass spectrometry-traceable modification diet of renal
disease 4-variable equation [34]: GFR (mL/min/1.73 m2)Z
175 (SCr)1.154 (age)0.203 (0.742 if female), where
SCr is serum creatinine levels in mg/dL and age is in years.
Statistical analysis
The baseline characteristics and biochemical examinations
of the patients were compared by two-tailed unpaired t
tests, and p< 0.05 was considered statistically significant.
Data from the eight time points, including urinary NGAL,
Cys C, and U-ACR, were analyzed by two-way repeated
measures ANOVA in order to evaluate time and time-by-
group interactions. The predictive value of urinary NGAL
levels for AKI after cisplatin infusion over baseline and of
other baseline covariates (i.e., age, sex, body mass index,
serum creatinine levels, and urinary total protein at base-
line) were analyzed by multivariate logistic regression. All
statistical analyses were performed with SPSS software
(version 18.0; 2009; IBM Corporation, Armonk, NY, USA).
The receiver operating characteristic (ROC) curves were
constructed and compared using STATA software (StataCorp
LP, College Station, TX, USA).
Results
Baseline characteristics
Forty-seven cancer patients were screened for study
enrollment, and 13 were excluded based on the exclusion
criteria. Of the 34 patients who provided consent, 33
completed the protocol. The reasons for failures to
complete the protocol included an unanticipated septic
shock within 2 days of cisplatin infusion. Twenty-four of
these patients (73%) had head and neck cancer and 21 (64%)
had Stage IV cancer. Other baseline characteristics are
listed in Table 1. There was no hematuria or proteinuria as
measured by urine dipstick at the precisplatin infusion
baseline, and the urinary protein-to-creatinine ratio
between groups was not significantly different (AKI,
0.2 0.3 vs. no AKI, 0.1 0.1 mg/mg; pZ 0.08).
Of the 33 study patients, 10 (30%) were in the cisplatin-
induced AKI risk class, which was defined by a decline in
eGFR levels of over 25% on Day 4 compared to baseline,
according to the RIFLE criteria [17]. In the AKI group, the
eGFRs progressively declined after cisplatin infusion and
were significantly lower than at baseline (121.5 31.4 mL/
min/1.73 m2) on Day 4 (95.1 22.1 mL/min/1.73 m2,
pZ 0.04) and Day 10 (87.9 20.8 mL/min/1.73 m2,
pZ 0.01). While the baseline eGFR was 95.1 26.0 mL/
min/1.73 m2, there were no discernable changes in the no
AKI group on Day 4 (94.9 24.1 mL/min/1.73 m2; pZ 0.95)
or Day 10 (96.0 26.5 mL/min/1.73 m2; pZ 0.97).
On Day 17, the eGFR (98.3 27.1 mL/min/1.73 m2)
tended to recover towards baseline in eight cases (80%) of
the AKI group. In the other two cases, serum creatinine
Table 1 Baseline characteristics of patients.
Total (nZ 33) AKI (nZ 10) No AKI (nZ 23) p
Demographic characteristics
Age (y) 50.1 8.6 51.1 9.3 49.8 8.5 0.69
Male 27 (87.1%) 9 (90%) 18 (85.7%) 0.81
BMI (kg/m2) 22.0 3.7 20.1 2.3 22.8 3.9 0.07
Clinical characteristics
SCr (mg/L) 8.0 2.0 7.0 2.0 9.0 2.0 0.08
WBC (109 cells/L) 8.6 9.5 8.6 4.6 8.7 11.0 0.99
Hb (g/L) 115 13 119 13 114 13 0.28
PLT (109/L) 261.8 140.9 303.9 121.7 243.5 147.2 0.26
AST (U/L) 23.0 9.0 24.4 11.4 22.3 8.2 0.52
ALT (U/L) 23.4 10.2 27.1 32.7 22.9 9.9 0.71
Na (mEq/L) 138.6 4.2 138.3 3.0 138.7 4.7 0.79
K (mEq/L) 4.6 3.2 3.8 0.5 4.9 2.6 0.56
Chemotherapy regimen
PF 27 (82%) 9 (90%) 18 (78%) 0.21
PFL 5 (15%) 1 (10%) 4 (17%) 0.42
Cisplatinþ docetaxel 1 (3%) d 1 (4%) 0.34
Type of malignancy
HN 24 (73%) 6 (60%) 18 (78%) 0.16
Esophageal 8 (24%) 4 (40%) 4 (17%) 0.08
Thymic 1 (3%) d 1 (4%) 0.50
Stage (II/III/IV) 1/11/21 0/5/5 1/6/16 0.50/0.08/0.16
Data are expressed as mean SD.
AKIZ acute kidney injury; ; ALTZ alanine aminotransferase; ASTZ aspartate aminotransferase; BMIZ body mass index; HBZ he-
moglobin; ; HNZ head and neck cancer; PFZ cisplatinþ fluorouracil; PFLZ cisplatinþ fluorouracilþ leucovorin; PLTZ platelets;
SCrZ serum creatinine; WBCZwhite blood cells.
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baseline.Urinary NGAL
There was no significant difference between baseline
urinary NGAL values in the AKI and no AKI groups without
creatinine correction (17.2 14.1 vs. 7.3 11.1 ng/mL;
pZ 0.061). Urinary NGAL values are usually reported as
urinary concentrations indexed to urinary creatinine
excretion [subsequently referred to as urinary NGAL levels
and expressed in ng NGAL/mg of creatinine (ng/mg)]. There
was no significant difference in the baseline urinary NGAL
concentrations between groups (AKI vs. no AKI, pZ 0.28;
Fig. 1A). The urinary concentrations of NGAL increased in
all individuals following cisplatin infusion despite the
administration of large amounts of hydration. Compared to
baseline, urinary NGAL values were significantly increased
at 12 hours (64.6 54.6 ng/mg, pZ 0.01) and on Day 1
(75.7 68.3 ng/mg, pZ 0.01), Day 2 (81.9 83.5 ng/mg,
pZ 0.02), and Day 3 (43.8 33.0 ng/mg, pZ 0.04) in the
AKI group. In the no AKI group, urinary NGAL values were
not significantly increased at 12 hours (14.0 12.8 ng/mg,
pZ 0.26) or on Day 1 (11.0 16.3 ng/mg, pZ 0.77), Day 2
(16.1 19.8 ng/mg, pZ 0.025), or Day 3 (12.5 14.8 ng/
mg, pZ 0.50) compared to baseline. The magnitude of
these changes over time differed significantly by group
(time-by-group interaction, p< 0.001, by repeated-
measures ANOVA; Fig. 2A).Urinary Cys C
Urinary Cys C values are reported as urinary concentrations
indexed to urinary creatinine excretion [referred to as
urinary Cys C and expressed in mg Cys C/g of creatinine
(mg/g)]. There was no significant difference in baseline
urinary Cys C concentrations between the groups (AKI vs. no
AKI, pZ 0.94; Fig. 1B). Urinary Cys C was not significantly
increased compared to baseline in the AKI group. In the no
AKI group, although urinary Cys C values were significantly
increased compared to baseline on Day 1 (9.3 6.9 mg/g,
pZ 0.005) and Day 2 (9.7 9.9 mg/g, pZ 0.02), the
magnitude of these changes over time did not differ
significantly by group (pZ 0.913, by repeated-measures
ANOVA; Fig. 2B).
Albumin to creatinine ratio
The ACR is expressed in mg albumin/mg of creatinine (mg/
mg). There was no significant difference in the baseline
ACRs between the two groups (AKI vs. no AKI, pZ 0.78;
Fig. 1C). The ACR was increased in all individuals following
cisplatin infusion despite large amounts of hydration.
Compared to baseline, the ACR values were increased
significantly at 8 hours (29.6 19.2 mg/mg, pZ 0.03) and
on Day 4 (55.6 51.9 mg/mg, pZ 0.02) in the AKI group. In
the no AKI group, although the ACR values were signifi-
cantly increased at 4 hours (29.6 23.7 mg/mg, pZ 0.001)
and 8 hours (25.3 16.7 mg/mg, pZ 0.001), and on Day 2
Figure 1. (A) Baseline urinary neutrophil gelatinase-
associated lipocalin (NGAL) excretion (mean SD). There was
no significant difference in the baseline urinary NGAL
concentrations between groups (AKI vs. no AKI, pZ 0.28). (B)
Baseline urinary cystatin C excretion (mean SD). There was
no significant difference in baseline urinary Cys C concentra-
tions between the groups (AKI vs. no AKI, pZ 0.94). (C)
Baseline urinary albumin to creatinine ratio (ACR) secretion
(mean SD). There was no significant difference in the base-
line ACRs between the two groups (AKI vs. no AKI, pZ 0.78).
308 H.Y.-H. Lin et al.(25.8 16.8 mg/mg, pZ 0.001), Day 3 (34.0 30.7 mg/mg,
pZ 0.001), and Day 4 (29.5 22.5 mg/mg, pZ 0.001)
compared to baseline, the magnitude of changes over time
did not differ significantly by group (pZ 0.183, by
repeated-measures ANOVA; Fig. 2C).ROC curves
The ROC curves were constructed in order to test the ability
of urinary biomarkers to predict AKI (Table 2). The AUC of
urinary NGAL levels at 8 hours postcisplatin was 0.76 [95%
confidence interval (CI)Z 0.58e0.94; pZ 0.021], and it
was 0.87 (95% CIZ 0.69e1; pZ 0.001) at 12 hours (Fig. 3),
0.87 (95% CIZ 0.7e1; pZ 0.001) at 24 hours, and 0.80 (95%
CIZ 0.59e1; pZ 0.008) at 48 hours. There were no
significant differences between the AUCs. Other urinary
biomarkers, including urinary Cys C and ACR, did notprovide significant predictive values at these time points
(Table 2).
Predictive value of urinary NGAL
To examine if urinary NGAL had a predictive ability beyond
that provided by more standard risk factors (e.g., age, sex,
body mass index, baseline creatinine, and urinary total
protein values), a multivariate logistic regression model
was used. Urinary NGAL that was increased at 12 hours
postcisplatin (pZ 0.045) was a significant predictor of AKI.
Discussion
The present study compared the roles of urinary NGAL, Cys
C, and ACR in cisplatin-induced AKI. The results showed
that urinary NGAL levels, which had values that were
customarily indexed to urine creatinine, were increased
significantly at 12 hours and on Days 1, 2, and 3 post-
cisplatin infusion compared to baseline in the AKI group.
After statistical analysis, the urinary NGAL values at 12
hours postcisplatin significantly predicted the risk of AKI
based on the RIFLE criteria. Changes in urinary NGAL values
occurred earlier than those in previous reports [32]. Other
urinary biomarkers such as Cys C and ACR may change at
several time points after cisplatin infusion, but their values
were not predictive of cisplatin-induced AKI. Other findings
were similar to those in previous reports where one-third of
patients still suffered AKI despite treatment with mannitol
and large amounts of hydration before cisplatin [2,11].
The use of NGAL levels as an AKI biomarker success-
fully passed through the preclinical, assay development,
and initial clinical testing stages of biomarker develop-
ment. It has now entered the prospective screening stage
for many kinds of AKI [22,31]. The NGAL levels may be the
answer in the search for a troponin-like biomarker for
AKI. Nonetheless, a persistent question is whether or not
a single marker like NGAL will be sufficient for cisplatin-
induced AKI, which has multiple targets of injury. In
order to diagnose and prevent cisplatin-induced AKI early,
it is necessary to identify the injured renal part and
monitor the disease progression. NGAL is an injury marker
of the renal tubules and other renal part injury markers,
such as Cys C and albuminuria, may compromise the
defect [35].
The present study showed that, even with large amounts
of hydration, urinary NGAL values were significantly
increased at 12 hours postcisplatin in a group of patients
who fulfilled the risk classification of the RIFLE criteria. The
magnitude of the urinary NGAL level increase was not as
high as those previously reported in ischemic AKI studies
[21,31]. This may indicate that urinary NGAL is a very
sensitive biomarker in detecting subclinical renal damage,
which is hard to detect using previous renal function
parameters.
Cisplatin-induced AKI is a major side effect in the clin-
ical use of cisplatin. Numerous approaches have been re-
ported to explore renal protection strategies, including
hydration, combined with mannitol or furosemide [9,10].
The unsatisfactory results may be due to multiple targets in
cisplatin-induced AKI. How to approach the balance
Figure 2. (A) Urinary NGAL excretion (mean SD) over time after cisplatin infusion in the acute kidney injury (AKI) and no AKI
groups. There was no significant difference at baseline (pZ 0.28), but there was a significant change over time (p< 0.001)
according to repeated-measures ANOVA, with increases in urinary NGAL excretion (*p< 0.05) compared to baseline. (B) Urinary
cystatin C secretion (mean SD) at baseline and the postcisplatin infusion time points in the AKI and no AKI groups. There was no
significant difference either at baseline (pZ 0.94) or over time (pZ 0.913) in the repeated-measures ANOVA. (C) Urinary ACR
secretion (mean SD) at baseline and in the postcisplatin infusion time points in the AKI and no AKI groups. There was no significant
difference at baseline (pZ 0.78) or over time (pZ 0.183) according to repeated-measures ANOVA. The urinary ACR increased
considerably after cisplatin infusion (*p< 0.05) compared to baseline in 2 time points in the AKI group.
Urinary NGAL and cisplatin-induced AKI 309between anticancer and renal protection is a clinical
dilemma when using cisplatin. This may be the reason why
renal protection strategies only offer partial effects,
especially if the renal protective approach interferes withthe anticancer effects, which is unacceptable. The devel-
opment of AKI biomarkers is a new direction in the
prevention of cisplatin-induced AKI. The earlier timing of
diagnosis allows for more renal protective strategies. The
Table 2 Area under the curve AUC for receiver operating
characteristic curves of urinary biomarkers for predicting
acute kidney infection.
Time Urinary NGAL Urinary cystatin C ACR
AUC 95% CI AUC 95% CI AUC 95% CI
0 h 0.67 0.47e0.87 0.48 0.23e0.73 0.43 0.19e0.68
4 h 0.68 0.47e0.88 0.64 0.43e0.85 0.52 0.29e0.75
8 h 0.76 0.58e0.94 0.62 0.41e0.83 0.53 0.28e0.79
12 h 0.87 0.69e1 0.53* 0.31e0.76 0.52* 0.27e0.76
24 h 0.87 0.7e1 0.63 0.4e0.85 0.52* 0.28e0.77
48 h 0.80 0.59e1 0.53 0.33e0.74 0.52 0.28e0.75
72 h 0.8 0.62-0e98 0.48 0.27e0.7 0.48* 0.25e0.7
96 h 0.81 0.64e0.97 0.51 0.3e0.72 0.7 0.49e0.91
*p< 0.05 versus urinary neutrophil gelatinase-associated lip-
ocalin (NGAL).
CIZ confidence interval.
310 H.Y.-H. Lin et al.increase in urinary NGAL suggests that the presence of
tubular injury is the major target of cisplatin-induced AKI.
The definition of the risk classification in the RIFLE criteria
is that a 25% decrease in eGFR indicates subclinical renal
damage that is usually neglected by clinicians. This study
demonstrates that urinary NAGL is significantly increased
earlier than other urinary biomarkers and is a useful
predictive marker of cisplatin-induced AKI.
In this study, urinary NGAL levels at baseline were
elevated in both the AKI (16.4 21.5 ng/mg) and no AKI
(9.9 12.7 ng/mg) groups. The increased urinary NGAL
levels may be due to the advanced stage of cancer in these
patients. Previous studies have proven that NGAL is
increased in cancer patients [36,37]. Most patients in this
study had Stage IV cancer (mean, 64%; AKI, 50% vs. no AKI,
69%). Recent findings suggest that NGAL activelyFigure 3. The receiver operating characteristic curves for
urinary biomarkers at 12 hours after postcisplatin infusion. The
area under the curve was greatest for urinary NGAL [0.87; 95%
confidence interval (CI): 0.69e1], which was followed by
urinary Cys C (0.53; 95% CI: 0.31e0.76), and then urinary ACR
(0.52; 95% CI: 0.27e0.76). Urinary NGAL was the only
biomarker to significantly predict the future development of
AKI.participates in the processes underlying the growth,
development, and differentiation of different human
tissues, including tumors [38]. Disease characteristics may
explain the differences in baseline urinary NGAL. The
difference between the two study groups was not signifi-
cant, but, due to the small patient number in each group,
a larger study is warranted for the clinical validation of this
difference.
Although a previous report showed that serum Cys C may
be a biomarker for the assessment of renal function in
cisplatin chemotherapy [33], urinary Cys C was not a useful
marker for detecting cisplatin-induced AKI in the present
study. While the U-ACR increased in both the AKI and no AKI
groups in this study, there was no statistically significant
difference. This result may have been due to the small
number of patients, and a larger study may be needed to
evaluate the role of U-ACR in cisplatin-induced AKI.
This study had some limitations. First, this was a single-
center study of limited size, and, thus, the power was not
sufficient to draw definitive conclusions. Larger studies are
necessary for clinical validation. Second, the follow-up
time was short and did not reveal if the increase in urinary
NGAL correlated with a long-term decline in renal function,
renal replacement therapy, or mortality.
In conclusion, our study found that increased urinary
NGAL was a useful biomarker of AKI in adults following
cisplatin treatment, and it was better than albuminuria or
urinary Cystatin C. The “window of opportunity” is narrow
in cisplatin-induced AKI, and time is limited for introducing
proper treatment after the initiating insult. Therefore, the
search for a new biomarker of renal dysfunction continues.
Due to its sensitivity and specificity, NGAL could be valu-
able in the detection of AKI.Acknowledgments
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